Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report
Open Access
- 1 January 2020
- journal article
- research article
- Published by Kare Publishing in Dusunen Adam the Journal of Psychiatry and Neurological Sciences
- Vol. 33 (1), 92-95
- https://doi.org/10.14744/dajpns.2019.00065
Abstract
Paliperidone palmitate (PP) is a long-acting antipsychotic administered intramuscularly once a month in the acute and maintenance treatments of schizophrenia. It has been reported to be successful especially in patients with poor oral drug compliance. The most common side effects are dizziness, sleepiness, anxiety, injection site reactions, and extrapyramidal system symptoms. The aim of this study is to draw attention to a rare side effect of PP and contribute to the literature by presenting a case of high fever and high liver function tests after application of the first dose. Paliperidon palmitat (PP), şizofreninin akut ve sürdürüm tedavisinde ayda bir kez IM olarak uygulanan, uzun etkili bir antipsikotiktir. Özellikle oral ilaç uyumu iyi olmayan hastalarda başarılı olduğu bildirilmiştir. En sık görülen yan etkileri baş dönemsi, uykululuk, anksiyete, enjeksiyon bölgesi reaksiyonları ve ekstrapiramidal sistem belirtileridir. Bu yazıda ilk doz PP kullanımının hemen sonrasında yüksek ateş ve karaciğer fonksiyon testlerinde yükseklik gelişen bir olgunun tartışılması amaçlanmıştır.Keywords
This publication has 13 references indexed in Scilit:
- More on autoimmune hepatitis and acute hepatitis AEuropean Journal of Gastroenterology & Hepatology, 2016
- A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry, 2012
- Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInternational Clinical Psychopharmacology, 2010
- Once-monthly paliperidone injection for the treatment of schizophreniaNeuropsychiatric Disease and Treatment, 2010
- A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in SchizophreniaNeuropsychopharmacology, 2010
- A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated SchizophreniaJournal of Clinical Psychopharmacology, 2010
- Efficacy of atypicalv.typical antipsychotics in the treatment of early psychosis: meta-analysisThe British Journal of Psychiatry, 2010
- Remission of Drug-Induced Hepatitis After Switching from Risperidone to PaliperidoneAmerican Journal of Psychiatry, 2010
- Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInternational Journal of Neuropsychopharmacology, 2009
- The case for long‐acting antipsychotic agents in the post‐CATIE eraActa Psychiatrica Scandinavica, 2007